Beyondspring Inc
NASDAQ:BYSI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Beyondspring Inc
NASDAQ:BYSI
|
US |
Intrinsic Value
The intrinsic value of Beyondspring Inc (BYSI) under the Base Case is 0.2242 USD per share.
Compared with the current market price of 0.4451 USD, the stock appears
Overvalued by 50% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Beyondspring Does
BeyondSpring is a biopharmaceutical company focused on developing cancer drugs, especially treatments that help patients cope with the side effects of chemotherapy and stimulate the immune system. Its best-known program is plinabulin, a drug studied for preventing chemotherapy-induced neutropenia, a condition where white blood cell counts drop and infection risk rises. The company also works on other cancer-related drug programs, but its core business is drug development rather than selling a broad line of commercial medicines.
- Headquarters
- United States of America US
- Employees
- 44
- IPO date
- Mar 9, 2017
Revenue & Expenses Breakdown
Beyondspring Inc
Earnings Waterfall
Beyondspring Inc
The intrinsic value for Beyondspring Inc (BYSI) under the Base Case is 0.2242 USD.
Compared with the current market price of 0.4451 USD, the stock appears Overvalued by 50% .